Skip to main content
Erschienen in:

Open Access 22.04.2024 | Research

High cure rates of Mycoplasma genitalium following empiric treatment with azithromycin alongside frequent detection of macrolide resistance in Austria

verfasst von: David Chromy, Lisa Starossek, Katharina Grabmeier-Pfistershammer, Sarah Adamek, Felix Maischack, Stefanie Sammet, Birgit Sadoghi, Georg Stary, Birgit Willinger, Wolfgang Weninger, Stefan Esser, Athanasios Makristathis, Wolfgang Michael Bauer

Erschienen in: Infection | Ausgabe 5/2024

Abstract

Background

Mycoplasma genitalium (MG) is an emerging sexually transmitted infection, often harboring resistance-associated mutations to azithromycin (AZM). Global surveillance has been mandated to tackle the burden caused by MG, yet no data are available for Austria. Thus, we aimed to investigate the prevalence of MG, disease characteristics, and treatment outcomes at the largest Austrian HIV—and STI clinic.

Methods

All MG test results at the Medical University of Vienna from 02/2019 to 03/2022 were evaluated. Azithromycin resistance testing was implemented in 03/2021.

Results

Among 2671 MG tests, 199 distinct and mostly asymptomatic (68%; 135/199) MG infections were identified, affecting 10% (178/1775) of all individuals. This study included 83% (1479/1775) men, 53% (940/1775) men who have sex with men (MSM), 31% (540/1754) HIV+, and 15% (267/1775) who were using HIV pre-exposure prophylaxis (PrEP). In logistic regression analysis, ‘MSM’ (aOR 2.55 (95% CI 1.65–3.92)), ‘use of PrEP’ (aOR 2.29 (95% CI 1.58–3.32)), and ‘history of syphilis’ (aOR 1.57 (95% CI 1.01–2.24) were independent predictors for MG infections. Eighty-nine percent (178/199) received treatment: 11% (21/178) doxycycline (2 weeks), 52% (92/178) AZM (5 days), and 37% ( 65/178) moxifloxacin (7–10 days) and 60% (106/178) had follow-up data available showing negative tests in 63% (5/8), 76% (44/58) and 85% (34/40), respectively. AZM resistance analysis was available for 57% (114/199)) and detected in 68% (78/114). Resistance-guided therapy achieved a cure in 87% (53/61), yet, empiric AZM-treatment (prior to 03/2021) cleared 68% (26/38).

Conclusions

Mycoplasma genitalium was readily detected in this Austrian observational study, affected predominantly MSM and often presented as asymptomatic disease. We observed a worryingly high prevalence of AZM resistance mutations; however, empiric AZM treatment cleared twice as many MG infections as expected.
Hinweise

Supplementary Information

The online version contains supplementary material available at https://​doi.​org/​10.​1007/​s15010-024-02261-6.

Introduction

Mycoplasma genitalium (MG) is an exceptionally small bacterium without a cell wall that can manifest as sexually transmitted infection (STI) [1]. It typically causes non-gonococcal urethritis or cervicitis in women and has also been associated with complications like pelvic inflammatory disease or preterm delivery [2]. Proctitis in men who have sex with men (MSM) caused by MG has also been described [3]. Nonetheless, a substantial proportion of MG infections remain entirely asymptomatic [4, 5] and it has been estimated that up to 3% of the general population are carriers of MG [6, 7]. The prevalence of MG increases to 6–17% for individuals seeking an STI clinic and for MSM using HIV pre-exposure prophylaxis (PrEP) [811], and a recent report described a MG prevalence of 20% in Swiss MSM living with HIV [12].
Management of MG infections can be challenging for several reasons. Culturing of MG requires an exceptionally high effort is time consuming, and thus, culture is not realizable for clinical diagnostics or phenotypic resistance analysis [13]. The gold standard to diagnose MG infections is currently a nucleic acid amplification test (NAAT) and a linked genotypic resistance analysis. There is, however, only a very limited number of commercially available kits for MG analysis hampering the access to sufficient MG diagnostics globally [14]. Furthermore, MG is intrinsically resistant to various antibiotics, limiting the current therapeutic armamentarium to tetracyclines, macrolides, and fluoroquinolones [13, 14]. Doxycycline is significantly less efficacious in clearing MG than azithromycin [14] and, therefore, can only be considered an alternative treatment option [14]. However, using azithromycin or moxifloxacin for MG management is also increasingly problematic due to antimicrobial resistance development [15]. Several studies have reported macrolide and fluoroquinolone resistance of 78–95% and 3–36%, respectively, in selected groups of MSM [12, 1619]. For that reason, the latest MG treatment guidelines by the Center for Disease Control and Prevention (CDC) [20], the latest revision of the British Association for Sexual Health and HIV (BASHH) guidelines [21], as well as the European STI treatment guidelines [14] have incorporated a recommendation for antimicrobial resistance testing prior to MG treatment. However, the limited availability of MG resistance testing is acknowledged [14, 20].
To overcome these challenges in managing MG, global surveillance and thorough assessment of regional antimicrobial resistance dynamics have been suggested [5]. Yet, no epidemiologic data on MG, including antimicrobial resistance, are available for Austria. We thus aimed to investigate the prevalence of MG among all individuals tested for STIs at the HIV/STI outpatient clinic of the Medical University of Vienna, analyze predictors for testing positive for MG, and assess details of antimicrobial resistance and the treatment responses.

Patients and methods

Study design and population

For this observational single-center study, all MG tests collected at the HIV and STI outpatient clinic at the Vienna General Hospital were systematically analyzed. The Vienna General Hospital works in conjunction with the Medical University of Vienna and is Austria´s largest tertiary care facility. Notably, it is also one of the few providers of HIV and PrEP services in Austria and open for STI testing without a referral—comparable to a ‘walk-in-clinic’ design. MG NAAT first became available at our clinic in 02/2019. Since then, all individuals screened for STIs were also tested for MG until 03/2022—at this time, the latest revision of the European guidelines on the management of MG had been published advising against screening for MG [14]. Accordingly, the study population comprised people living with HIV (PLWH; usually tested annually and/or if symptomatic), PrEP users (usually tested every 3 months and/or if symptomatic), symptomatic individuals presenting for STI workup, and asymptomatic individuals presenting for STI screening. Results on MG tests were systematically retrieved, whereas clinical data were collected from the medical history.

Definitions

Each test for MG included a unique time point at which a single individual was tested for MG at one or more locations. The tested locations were defined at the discretion of the physician based on the reported sex practices: typically, an STI workup for MSM includes pharyngeal, urethral, and anal sampling, for all women pharyngeal, urethral, and cervical sampling and for heterosexual men urethral sampling. An individual was defined as a single person, whereas an ‘episode’ was defined as at least one positive MG test for an individual. If more than one sample tested positive from a single individual at a given time (i.e., multiple sites were infected), this was also considered a single episode. If more than one positive MG test was available for a single individual at different time points and the individuals had tested negative at the affected location in between, it was considered a new episode/reinfection.
Individuals using ‘daily’ or ‘on-demand’ PrEP at the time of sample collection were considered as PrEP users. ‘History’ of HIV post-exposure prophylaxis (PEP) was defined by previous use of antiretroviral therapy (ART) other than PrEP in the absence of HIV infection. ‘History of syphilis’ was considered in individuals with positive Treponema pallidum specific test plus documented previous treatment for syphilis, whereas ongoing coinfection with syphilis was based on positive serology including a non-specific Treponema pallidum test plus clinical documentation. Coinfection with Neisseria gonorrhoeae or Chlamydia trachomatis was defined by a positive result obtained via NAAT at the time of MG infection.

Mycoplasma genitalium test

A physician or trained nursing personnel performed pharyngeal, anal, and cervical sampling using the FLOQSwabs® and UTM-RT mini transport medium (Copan, Italy). For urethral sampling, neat urine was collected. The DNA extraction was performed using the BD MAX™ EXK™ DNA-1 kit (Becton Dickinson, Heidelberg, Germany) followed by a multiplex PCR utilizing the BioGX Mycoplasma-Ureaplasma—OSR for BD MAX kit (BioGX, Birmingham, AL, USA) on a BD MAX system (Becton Dickinson). Azithromycin resistance analysis became available in 03/2021 and was performed using a ResistancePlus® Mycoplasma genitalium FleXible kit (SpeeDx, London, UK) in conjunction with the GeneXpert system (Cepheid, Sunnyvale, CA, USA).

Treatment

Treatment was based on European guidelines applicable at the respective time of infection [22]: doxycycline 100 mg twice daily for 2 weeks, azithromycin 500 mg day one followed by 250 mg for four consecutive days, or moxifloxacin 400 mg once daily for 7–10 days. A test of cure was usually performed 3–4 weeks after therapy had been completed. If no negative test had been available following treatment or a positive test that had been collected less than 3 weeks after completion of therapy (i.e., false positivity cannot be ruled out), data on treatment outcome were considered missing.

Statistical analysis

GraphPad Prism 9 (GraphPad Software, La Jolla, CA, USA) and IBM SPSS Statistics 28 (IBM, Armonk, NY, USA) were used to perform the statistical analyses. Continuous variables are presented as mean ± standard deviation and group comparisons were performed with independent sample Student´s t-test. Nominal variables are plotted as number and percentage of individuals with a specific feature and group comparison was done by Pearson’s Chi-squared test or Fisher’s exact test. Binary logistic regression models were applied to investigate risk factors to test positive for MG. A sub-analysis for PrEP users with consecutive follow-up was computed using a survival analysis and presented as Kaplan–Meier curves. The level of significance for the statistical analyses was set at 0.05.

Ethics

The present study complies with the ethical standards of the 1964 Declaration of Helsinki and its later amendments. The ethical approval was provided by the respective local ethics committees, i.e., the Medical University of Vienna (2175/2020). Due to the retrospective design, the need for an informed consent had been waived.

Results

Prevalence of Mycoplasma genitalium

Throughout the observational period of 3 years, 2671 tests for MG were performed in 1775 individuals. The mean age of the study population was 35.6 ± 10.7 years, the majority were male (83%, 1479/1775), and 53% (940/1775) were MSM. A substantial number of tested individuals were PLWH (30%, 540/1775) or PrEP users (15%, 267/1775) and had previously been infected with syphilis (27%, 486/1775). The overall MG prevalence was 7% (199/2671); however, 10% (178/1775) of all individuals were tested at least once positive for MG (Fig. 1). Within the first 2 years in which no azithromycin resistance testing was available, 43% (85/199) of all episodes were documented. Notably, limited STI testing access and non-availability of MG NAATs led to a marked decline in MG tests from 03/2020 to 09/2020. Yet, the positivity rate remained relatively stable throughout the observational period (Fig. 2A). Sixty-eight percent (135/199) of MG infections were asymptomatic, whereas 22% (43/199), 8% (15/199), 1% (1/199), and 3% (5/199) presented with urethritis, proctitis, pharyngitis, and cervicitis, respectively (Table 1). Since coinfections with gonorrhea (13%, 26/199), chlamydia (19%, 37/199), and syphilis (14%, 28/199) were common, we performed a sub-analysis assuming that symptoms in individuals with a coinfection were solely due to chlamydia or gonorrhea and not caused by MG (Table S1). In that ‘over-corrected’ scenario, up to 77% of MG episodes would have been considered asymptomatic.
Table 1
Patient characteristics and comparison of azithromycin-resistant Mycoplasma genitalium episodes vs. all other episodes
 
All episodes
N = 199
Azithromycin resistance negative or non-available episodes
N = 121
Azithromycin-resistant episodes
N = 78
p value
Age
35.6 ± 10.7
34.9 ± 11.7
36.9 ± 9.0
0.203
Male
93% (185/199)
89% (108/121)
99% (77/78)
0.011
MSM
81% (161/199)
73% (88/121)
94% (73/78)
<0.001
On HIV PrEP
39% (78/199)
35% (42/121)
46% (36/78)
0.106
HIV
33% (65/199)
30% (36/121)
37% (29/78)
0.275
History of HIV PEP
12% (23/199)
10% (12/121)
14% (11/78)
0.367
History of syphilis
44% (87/199)
42% (51/121)
46% (36/78)
0.578
Leading symptom
 Asymptomatic
68% (135/199)
65% (79/121)
72% (56/78)
0.004
 Urethritis
22% (43/199)
27% (33/121)
13% (10/78)
 
 Proctitis
8% (15/199)
3% (4/121)
14% (11/78)
 
 Pharyngitis
1% (1/199)
1% (1/121)
0% (0/78)
 
 Cervicitis
3% (5/199)
3% (4/121)
1% (1/78)
 
Site of manifestationa
 Urethral
55% (110/199)
67% (81/121)
37% (29/78)
<0.001
 Anal
40% (80/199)
28% (34/121)
59% (46/78)
 
 Pharyngeal
2% (4/199)
2% (2/121)
3% (2/78)
 
 Cervical
3% (5/199)
3% (4/121)
1% (1/78)
 
Treatment
89% (178/199)
89% (108/121)
90% (70/78)
0.913
 Doxycycline
11% (21/178)
13% (14/108)
10% (7/70)
0.580
  Negative follow-up test
63% (5/8)
57% (4/7)
100% (1/1)
 Azithromycin
52% (92/178)
84% (91/108)
1% (1/70)
<0.001
  Negative follow-up test
76% (44/58)
76% (44/58)
 Moxifloxacin
37% (65/178)
3% (3/108)
89% (62/70)
<0.001
  Negative follow-up test
85% (34/40)
N/A
85% (34/40)
Concomitant infection
 Gonorrhea
13% (26/199)
13% (16/121)
13% (10/78)
1
 Chlamydia
19% (37/199)
22% (27/121)
13% (10/78)
0.093
 Syphilis
14% (28/199)
11% (13/121)
19% (15/78)
0.093
HIV human immunodeficiency virus, MSM men who have sex with men, PEP post-exposure prophylaxis, PrEP pre-exposure prophylaxis
a 17 individuals were tested positive at more than one location: all seventeen tested positive at the urethra plus 12 and 5 at the anal mucosa and cervix, respectively. For the purpose of this analysis, these 17 cases were assigned to the non-urethral (i.e., anal or cervical) site only
Furthermore, we analyzed predictors for testing positive for MG. By deploying a binary logistic regression model (Table 2), we identified male (odds ratio 2.51, 95% confidence interval 1.43–4.40), MSM (OR 3.67, 95% CI 2.53–5.32), use of PrEP (OR 3.52, 95% CI 2.50–4.96), and previous syphilis (OR 2.21, 95% CI 1.61–3.04) as risk factors for acquiring MG. In multivariate analysis, MSM, use of PrEP, and previous syphilis remained independent predictors for testing positive for MG at an adjusted OR of 2.55 (1.65–3.92), 2.29 (1.58–3.32), and 1.57 (1.01–2.24), respectively.
Table 2
Risk factors to have at least one positive Mycoplasma genitalium test result
 
All individuals
N = 1775
Individuals without at least one MG positive test
N = 1597
Individuals with at least one MG positive test
N = 178
Odds ratio (95% CI)
p value
Adjusted odds ratio (95% CI)
p value
Age
 ≤24 years
13% (230/1775)
13% (205/1597)
14% (25/178)
1.00
   
 25–34 years
35% (617/1775)
35% (554/1597)
35% (63/178)
0.93 (0.57–1.5)
0.780
  
 ≥35 years
52% (928/1775)
52% (838/1597)
51% (90/178)
0.88 (0.55–1.41)
0.595
  
Sex
 Female
17% (296/1775)
18% (282/1597)
8% (14/178)
1.00
   
 Male
83% (1479/1775)
82% (1315/1597)
92% (164/178)
2.51 (1.43–4.40)
0.001
1.08 (0.57–2.06)
0.819
Transmission
 Heterosexual transmission or unknown
47% (835/1775)
50% 797(/1597)
21% (38/178)
1.00
   
 MSM
53% (940/1775)
50% (800/1597)
79% (140/178)
3.67 (2.53–5.32)
<0.001
2.55 (1.65–3.92)
<0.001
HIV Status
 No
70% (1214/1775)
77% (1214/1597)
65% (116/178)
1
   
 Yes
30% (540/1775)
23% (362/1597)
35% (62/178)
0.81 (0.58–1.12)
0.198
  
Use of pre-exposure prophylaxis for HIV
 No
85% (1508/1775)
87% (1391/1597)
66% (117/178)
1
   
 Yes
15% (267/1775)
13% (206/1597)
34% (61/178)
3.52 (2.50–4.96)
<0.001
2.29 (1.58–3.32)
<0.001
History of syphilis
 No
73% (1289/1775)
74% (1188/1597)
57% (101/178)
1.00
   
 Yes
27% (486/1775)
26% (409/1597)
43% (77/178)
2.21 (1.61–3.04)
<0.001
1.57 (1.01–2.24)
0.013
CI confidence interval, MG mycoplasma genitalium, MSM men who have sex with men

Antimicrobial resistance analysis

All positive MG tests since 03/2021 were subjected to antimicrobial resistance analysis, comprising 57% (114/199) of all isolates. Of those, 68% (78/114) harbored an azithromycin-resistant variant and the monthly proportion of resistant samples ranged from 50 to 82% during the observed period (Fig. 2B). By comparing azithromycin-resistant MG infections against all other MG episodes, we observed a significantly higher proportion of MSM (94%, 73/78 vs. 73%, 88/121; p < 0.001) among those resistant to azithromycin (Table 1). Furthermore, those with azithromycin resistance showed a higher percentage of anal infections (59%, 46/78 vs. 28%, 34/121; p < 0.001). In order to assess whether heterogeneity occurred between the first (without) and second (with azithromycin resistance test) half of the observational period within the study population, we compared patient characteristics of the two timespans (Table S2). MSM were more frequent (90%, 102/114 vs. 69%, 59/85) among those testing positive for MG in the second period (azithromycin resistance test available). Notably, MSM were also more often sampled in the more recent timespan (74%, 1041/1408 vs. 56%, 710/1263) and their positivity rate increased from 8% (59/710) to 10% (102/1041) while, for all non-MSM, it declined from 5% (26/553) to 3% (12/367).

Treatment and outcomes

Eighty-nine percent (178/199) of all MG episodes received treatment. Doxycycline, azithromycin, and moxifloxacin were used in 11% (21/178), 52% (92/178), and 37% (65/178) of patients. While the proportion of individuals treated with doxycycline did not change significantly throughout the study period, azithromycin was the primary choice (80%, 60/75) before antimicrobial resistance analysis became available. Moxifloxacin was almost exclusively used if resistance to azithromycin was detected: 89% (62/70) of those patients were treated with moxifloxacin.
Cure rates, defined by a negative follow-up test, were available for 60% (106/178) of all treated individuals and were more often available for PrEP users (aOR 2.14, 95% CI 1.09–4.19) (Table S3). Overall, doxycycline achieved clearance of MG in 63% (5/8), azithromycin in 76% (44/58), and moxifloxacin in 85% (34/40), whereas empiric treatment with azithromycin during non-availability of resistance analysis cleared 68% (26/38). Eighteen patients failing initial treatment had information on a consecutive therapy available: two had failed on doxycycline, eleven on azithromycin, and five on moxifloxacin. Both doxycycline patients plus one after azithromycin received another course of azithromycin, whereas all others were re-treated with moxifloxacin. A test of cure was available for twelve individuals, with 42% (5/12) testing again positive for MG. Since all five were asymptomatic males, no further treatment was pursued.

Discussion

Our study comprehensively evaluated 199 MG infections detected among 2671 tests taken from a representative sample of HIV/STI clinic attendees over 3 years. As the very first comprehensive epidemiologic data on MG in Austria, these results provide important insights into regional prevalence and antimicrobial resistance and fill a data gap in European MG surveillance. In our study, MG prevalence was stable at just below 10% and genotypic resistance to azithromycin was found in 68% of all tested isolates, predominantly affecting MSM. Surprisingly, we also observed high cure rates of 68% for empirically chosen treatment with azithromycin.
The prevalence of MG among individuals seeking an HIV/STI clinic observed in our study is comparable to other countries. A 2020 single-center study from an STI clinic in the UK found a MG prevalence of 11% [10] and another 2020 study conducted at a point-of-care STI testing facility in Spain observed a prevalence of 7% [23]. Of note, in both studies MSM were predominantly affected. A recently published systematic review analyzing MG in MSM reported a prevalence of 5% for the urethra and anal mucosa; however, the prevalence increased to 7% and 16%, respectively, in symptomatic individuals [24]. Accordingly, an increased prevalence of MG had been described for patients presenting with non-gonococcal urethritis: Pond M.J. and co-workers reported MG as the potential cause for urethritis in men in 17% [8]. Nonetheless, most MG infections remain silent without any symptom development. Up to 77% of the episodes of MG observed in our study were asymptomatic, corresponding to a German study that reported 71% of MG positive PrEP users as asymptomatic [11]. Due to this high number of asymptomatic MG carriers, it remained subject to debate whether screening for MG should be performed [7, 14, 24]. In particular, the increasing availability of PrEP and the consecutive surge in STI screening of highly exposed populations fueled this discussion—more tests will undoubtedly be accompanied by more diagnoses [9, 19]. In our sub-analysis of PrEP users, 28% tested positive for MG within 1 year. Ultimately, numerous STI guidelines have now recommended not to screen for MG in asymptomatic individuals [14, 20].
As far as we know, whether MG screening plus consecutive treatment could reduce the MG prevalence in selected populations (e.g., PrEP users) remains unclear. For chlamydia and gonorrhea, however, it has been calculated that in a scenario of 40% PrEP coverage for MSM at risk for HIV acquisition, quarterly STI checks could reduce both infections by 40% and 42%, respectively, within one decade [25]. Notably, this study did not include pharyngeal infection. In contrast, a study by Buyze J. and co-workers included pharyngeal infections and found only a negligible impact of frequent screening for gonorrhea on its prevalence among MSM [26]. This is in line with a systematic review from 2018 that reported no prevalence reduction of chlamydia and gonorrhea among MSM following screening implementation [27]. These results, however, cannot be directly applied to MG transmission dynamics since MG follows different epidemiologic characteristics [6, 13]. The increased proportion of asymptomatic carriers of MG would necessitate even higher screening efforts to reduce MG prevalence. In our study, positivity rates remained unchanged throughout 3 years of observation even though 89% of all MG episodes received treatment. Our work is clearly underpowered to demonstrate a longitudinal impact; still, we consider our work as a potential component for future modeling studies analyzing a ‘test and treat’ approach.
An important consideration regarding screening and treating MG is antimicrobial resistance emergence. MG is intrinsically susceptible to a very limited number of antibiotics and phenotypic resistance analysis is restricted to highly advanced research settings [13]. For the last decade, the empiric first-line treatment of MG was azithromycin; however, azithromycin was also used to treat chlamydia infections and gonorrhea [11]. The surge in STIs among MSM—to some extent facilitated by the upscale in STI screening—caused a high exposure to azithromycin and other antibiotics for this population [28], which, in turn, is associated with antimicrobial resistance development [29]. At the same time, numerous studies report increasing macrolide resistance rates of MG [4, 5, 12, 17, 18, 30, 31] and 68% of the MG isolates in our study harbored an azithromycin resistance mutation. Likewise, a recent report indicated that azithromycin-resistant N. gonorrhoeae in Europe rose from 2% in 2015 to 11% in 2019 among males [32]. However, the paradigm for the broad use of azithromycin in STI management is currently subject to change since doxycycline has shown a better efficacy for chlamydia in most settings [33, 34] and ceftriaxone monotherapy (i.e., not combined with azithromycin) for gonorrhea is now recommended by international guidelines [20, 35]. Of note, ceftriaxone monotherapy for gonorrhea was implemented at our clinic in 2013 and has been used exclusively since 2020 [36]. Whether these strategies combined with the recommendation to not screen for MG will lead to a reduction in azithromycin exposure and thus have a favorable impact on MG´s resistome will be subject to future studies. Until then, management of MG requires more differentiated strategies.
The American and European STI treatment guidelines now recommend a resistance-guided treatment of MG [14, 20]. Yet, they also appreciate the limited availability of reliable and commercially available kits for antimicrobial resistance analysis. Our clinic—a Central European tertiary care center—did not gain access to MG NAAT until 2019 and to azithromycin resistance testing until 2021; as of today, we have not implemented fluoroquinolone resistance analysis due to reliability concerns regarding the phenotypic/genotypic association of these tests [13] as well as limited availability of commercial kits.
The correlation of genotypic markers for phenotypic macrolide resistance is better established. Jensen J.S. and co-workers demonstrated increased minimum inhibitory concentrations for macrolides in 7 MG isolates after failing treatment with azithromycin and, correspondingly, detected mutations in the region V of the 23S rRNA gene [37]. Numerous other studies have either reported on the occurrence of these mutations or demonstrated a significantly higher prevalence of the genotypic markers among treatment failures [5, 8, 16, 18, 23, 30, 38, 39]. While these data imply a consistent sensitivity of 23S rRNA genotyping for macrolide treatment failure, it does not automatically suggest a reliable specificity of these markers. Trials assessing pretreatment genotypic macrolide resistance and not utilizing these results for treatment selection, thus providing a setting to determine specificity, typically used single-shot azithromycin [30, 37]. We observed relatively high cure rates of 68% following empiric treatment of a 5-day course of azithromycin from 02/2019 to 03/2021, although a worryingly high prevalence of 68% azithromycin resistance mutation was shown once testing became available. We did not see substantial changes in the patient population—at least no changes accounting for an effective doubling of the expected resistance—and we consider it unlikely that this high number of azithromycin resistance emerged within the last third of our 3-year observational period. Thus, we may speculate that 23S rRNA genotyping has limited specificity for treatment failure in a prolonged treatment course with azithromycin. Unfortunately, samples before 03/2021 were not stored and, thus, are unavailable to subject empirically treated MG isolates to resistance analysis to resolve this question.
We consider the high number of sampled individuals as the first strong aspect of this work. Secondly, we report the first data on the Austrian MG epidemiology. Furthermore, this study provides a comprehensive analysis of treatment and outcomes. While targeted therapy was not possible during the first half of the observational period due to the non-availability of resistance testing, it enabled us to investigate empiric treatment. The most important limitation of this study is its retrospective design, potentially introducing a variety of biases. It is the cause for incomplete outcome data (were available for 60%) which may have led to an over- or underestimation of treatment efficacy. Notably, treatment outcomes were more often available for PrEP users, while other patient characteristics were evenly distributed. Accordingly, in our study, individuals with missing treatment outcomes are more likely to belong to a population with a generally lower risk for harboring an azithromycin or fluoroquinolone-resistant MG strain. Therefore, we believe that the treatment efficacy in our dataset is more likely to be underestimated due to missing values. Finally, the retrospective design is also the reason why we cannot provide a post hoc resistance analysis of the isolates of the first study period.
In conclusion, the emergence of antimicrobial resistance in MG has necessitated epidemiologic surveillance and our work comprehensively fills a Central European gap by providing Austrian data. While most of our observations were in line with previous reports, we did see a discrepancy between empiric treatment outcomes following azithromycin and the results of the resistance analysis. Currently, a positive genotypic resistance test is obligatorily considered to cause treatment failure, yet our data suggest that future studies should further investigate the prevalence of 23S rRNA mutations among individuals successfully treated with macrolides.

Acknowledgements

The authors thank Cornelia Gabler and the IT4science team for their support with data acquisition.

Declarations

Conflicts of interest

DC served as a speaker and/or advisory board member for Gilead, ViiV Healthcare, and MSD and received travel support from MSD, ViiV Healthcare, and Gilead. LS has nothing to disclose. KGP served as a speaker and/or consultant and/or advisory board member for ViiV Healthcare and Gilead and received travel support from ViiV Healthcare and Gilead. SA has nothing to disclose. FM has nothing to disclose. SS served as advisory board member for MSD and received travel support from Gilead. BS received industry grants/royalties from Abbott/AbbVie, Almirall, Celgene, Eli Lilly, Galderma, Novartis, Pfizer, Trevi Therapeutics, UCB, Janssen Cilag. GS has nothing to disclose. BW served as a speaker for Gilead and advisory board member for MSD. WW served as a speaker, consultant, and/or advisory board member for LEO Pharma, Pfizer, Sanofi Genzyme, Eli Lilly, Novartis, Boehringer Ingelheim, AbbVie, and Janssen. SE served as a speaker and/or advisory board member for Gilead, GSK, Janssen, MSD, ViiV Healthcare, and MSD and received travel support from Gilead, Janssen, MSD, and ViiV Healthcare and research grant from Gilead, Janssen, MSD, and ViiV Healthcare. AM has nothing to disclose. WMB served as a speaker and/or consultant and/or advisory board member for AbbVie, ViiV Healthcare, and Takeda and received travel support from AbbVie, MSD, ViiV Healthcare, and Gilead.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​.

Unsere Produktempfehlungen

Neuer Inhalt

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

e.Med Innere Medizin

Kombi-Abonnement

Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

Weitere Produktempfehlungen anzeigen
Anhänge

Supplementary Information

Below is the link to the electronic supplementary material.
Literatur
4.
Zurück zum Zitat Dumke R, Ziegler T, Abbasi-Boroudjeni N, Rust M, Glaunsinger T. Prevalence of macrolide- and fluoroquinolone-resistant Mycoplasma genitalium strains in clinical specimens from men who have sex with men of two sexually transmitted infection practices in Berlin, Germany. J Glob Antimicrob Resist. 2019;18:118–21. https://doi.org/10.1016/j.jgar.2019.06.015.CrossRefPubMed Dumke R, Ziegler T, Abbasi-Boroudjeni N, Rust M, Glaunsinger T. Prevalence of macrolide- and fluoroquinolone-resistant Mycoplasma genitalium strains in clinical specimens from men who have sex with men of two sexually transmitted infection practices in Berlin, Germany. J Glob Antimicrob Resist. 2019;18:118–21. https://​doi.​org/​10.​1016/​j.​jgar.​2019.​06.​015.CrossRefPubMed
8.
Zurück zum Zitat Pond MJ, Nori AV, Witney AA, Lopeman RC, Butcher PD, Sadiq ST. High prevalence of antibiotic-resistant Mycoplasma genitalium in nongonococcal urethritis: the need for routine testing and the inadequacy of current treatment options. Clin Infect Dis. 2014;58:631–7. https://doi.org/10.1093/cid/cit752.CrossRefPubMed Pond MJ, Nori AV, Witney AA, Lopeman RC, Butcher PD, Sadiq ST. High prevalence of antibiotic-resistant Mycoplasma genitalium in nongonococcal urethritis: the need for routine testing and the inadequacy of current treatment options. Clin Infect Dis. 2014;58:631–7. https://​doi.​org/​10.​1093/​cid/​cit752.CrossRefPubMed
10.
12.
Zurück zum Zitat Ring A, Balakrishna S, Imkamp F, Burkard S, Triet F, Brunschweiler F, et al. High rates of asymptomatic Mycoplasma genitalium infections with high proportion of genotypic resistance to first-line macrolide treatment among men who have sex with men enrolled in the Zurich Primary HIV Infection Study. Open Forum Infect Dis. 2022;9:ofac217. https://doi.org/10.1093/ofid/ofac217.CrossRefPubMedPubMedCentral Ring A, Balakrishna S, Imkamp F, Burkard S, Triet F, Brunschweiler F, et al. High rates of asymptomatic Mycoplasma genitalium infections with high proportion of genotypic resistance to first-line macrolide treatment among men who have sex with men enrolled in the Zurich Primary HIV Infection Study. Open Forum Infect Dis. 2022;9:ofac217. https://​doi.​org/​10.​1093/​ofid/​ofac217.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Berçot B, Charreau I, Clotilde R, Delaugerre C, Chidiac C, Pialoux G, et al. High prevalence and high rate of antibiotic resistance of Mycoplasma genitalium infections in men who have sex with men. A sub-study of the ANRS ipergay PrEP trial. Clin Infect Dis. 2020;73:e2127–33. https://doi.org/10.1093/cid/ciaa1832.CrossRef Berçot B, Charreau I, Clotilde R, Delaugerre C, Chidiac C, Pialoux G, et al. High prevalence and high rate of antibiotic resistance of Mycoplasma genitalium infections in men who have sex with men. A sub-study of the ANRS ipergay PrEP trial. Clin Infect Dis. 2020;73:e2127–33. https://​doi.​org/​10.​1093/​cid/​ciaa1832.CrossRef
18.
Zurück zum Zitat De Baetselier I, Vuylsteke B, Reyniers T, Smet H, Van den Bossche D, Kenyon C, et al. Worryingly high prevalence of resistance-associated mutations to macrolides and fluoroquinolones in Mycoplasma genitalium among men who have sex with men with recurrent sexually transmitted infections. Int J STD AIDS. 2022;33:385–90. https://doi.org/10.1177/09564624211070704.CrossRefPubMed De Baetselier I, Vuylsteke B, Reyniers T, Smet H, Van den Bossche D, Kenyon C, et al. Worryingly high prevalence of resistance-associated mutations to macrolides and fluoroquinolones in Mycoplasma genitalium among men who have sex with men with recurrent sexually transmitted infections. Int J STD AIDS. 2022;33:385–90. https://​doi.​org/​10.​1177/​0956462421107070​4.CrossRefPubMed
23.
Zurück zum Zitat Fernández-Huerta M, Barberá MJ, Esperalba J, Fernandez-Naval C, Vall-Mayans M, Arando M, et al. Prevalence of Mycoplasma genitalium and macrolide resistance among asymptomatic people visiting a point of care service for rapid STI screening: a cross-sectional study. Sex Transm Infect. 2020;96:300–5. https://doi.org/10.1136/sextrans-2019-054124.CrossRefPubMed Fernández-Huerta M, Barberá MJ, Esperalba J, Fernandez-Naval C, Vall-Mayans M, Arando M, et al. Prevalence of Mycoplasma genitalium and macrolide resistance among asymptomatic people visiting a point of care service for rapid STI screening: a cross-sectional study. Sex Transm Infect. 2020;96:300–5. https://​doi.​org/​10.​1136/​sextrans-2019-054124.CrossRefPubMed
30.
Zurück zum Zitat Bissessor M, Tabrizi SN, Twin J, Abdo H, Fairley CK, Chen MY, et al. Macrolide resistance and azithromycin failure in a Mycoplasma genitalium-infected cohort and response of azithromycin failures to alternative antibiotic regimens. Clin Infect Dis. 2015;60:1228–36. https://doi.org/10.1093/cid/ciu1162.CrossRefPubMed Bissessor M, Tabrizi SN, Twin J, Abdo H, Fairley CK, Chen MY, et al. Macrolide resistance and azithromycin failure in a Mycoplasma genitalium-infected cohort and response of azithromycin failures to alternative antibiotic regimens. Clin Infect Dis. 2015;60:1228–36. https://​doi.​org/​10.​1093/​cid/​ciu1162.CrossRefPubMed
32.
Zurück zum Zitat European Center for Disease Control and Prevention. Gonococcal antimicrobial susceptibility surveillance in the EU/EEA: summary of results for 2019. Stockholm: ECDC; 2021. European Center for Disease Control and Prevention. Gonococcal antimicrobial susceptibility surveillance in the EU/EEA: summary of results for 2019. Stockholm: ECDC; 2021.
37.
Zurück zum Zitat Jensen JS, Bradshaw CS, Tabrizi SN, Fairley CK, Hamasuna R. Azithromycin treatment failure in Mycoplasma genitalium-positive patients with nongonococcal urethritis is associated with induced macrolide resistance. Clin Infect Dis. 2008;47:1546–53. https://doi.org/10.1086/593188.CrossRefPubMed Jensen JS, Bradshaw CS, Tabrizi SN, Fairley CK, Hamasuna R. Azithromycin treatment failure in Mycoplasma genitalium-positive patients with nongonococcal urethritis is associated with induced macrolide resistance. Clin Infect Dis. 2008;47:1546–53. https://​doi.​org/​10.​1086/​593188.CrossRefPubMed
38.
Zurück zum Zitat De Baetselier I, Kenyon C, Vanden Berghe W, Smet H, Wouters K, Van den Bossche D, et al. An alarming high prevalence of resistance-associated mutations to macrolides and fluoroquinolones in Mycoplasma genitalium in Belgium: results from samples collected between 2015 and 2018. Sex Transm Infect. 2020;97:297–303. https://doi.org/10.1136/sextrans-2020-054511.CrossRefPubMed De Baetselier I, Kenyon C, Vanden Berghe W, Smet H, Wouters K, Van den Bossche D, et al. An alarming high prevalence of resistance-associated mutations to macrolides and fluoroquinolones in Mycoplasma genitalium in Belgium: results from samples collected between 2015 and 2018. Sex Transm Infect. 2020;97:297–303. https://​doi.​org/​10.​1136/​sextrans-2020-054511.CrossRefPubMed
Metadaten
Titel
High cure rates of Mycoplasma genitalium following empiric treatment with azithromycin alongside frequent detection of macrolide resistance in Austria
verfasst von
David Chromy
Lisa Starossek
Katharina Grabmeier-Pfistershammer
Sarah Adamek
Felix Maischack
Stefanie Sammet
Birgit Sadoghi
Georg Stary
Birgit Willinger
Wolfgang Weninger
Stefan Esser
Athanasios Makristathis
Wolfgang Michael Bauer
Publikationsdatum
22.04.2024
Verlag
Springer Berlin Heidelberg
Erschienen in
Infection / Ausgabe 5/2024
Print ISSN: 0300-8126
Elektronische ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-024-02261-6

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Innere Medizin

Fünf Faktoren sagen Lymphödeme nach Brustkrebs voraus

Ob nach der operativen Behandlung von Brustkrebs ein Lymphödem droht, lässt sich anhand eines Risikomodells abschätzen, das auf fünf leicht verfügbaren klinischen Parametern beruht.

Metastasiertes CRC: besser Checkpointhemmer im Doppelpack!

Die Kombination von Nivolumab plus Ipilimumab ist beim metastasierten Kolorektalkarzinom mit MSI-H- oder dMMR klar im Vorteil gegenüber einer Nivolumab-Monotherapie: Das Progressionsrisiko war damit in einer Phase-3-Studie um 38% reduziert.

Riesenzellarteriitis: bilaterale Biopsie der Temporalarterien von Vorteil

Die Riesenzellarteriitis (RZA) erfordert eine rasche und präzise Diagnose, da innerhalb weniger Tage ein schwerer, irreversibler Sehverlust drohen kann. In diesem Zusammenhang scheint die bilaterale Biopsie der Temporalarterien (TAB) der unilateralen überlegen zu sein.

Große Trinkmengen bei Blasentumoren möglicherweise von Nachteil

Beim nicht-muskelinvasiven Blasenkrebs scheint eine hohe Flüssigkeitszufuhr keinen schützenden Effekt in Bezug auf das Risiko eines Rezidivs oder einer Krankheitsprogression zu haben. Eine niederländische Studie legt sogar nahe, dass große Trinkmengen das Fortschreiten der Erkrankung begünstigen könnten.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.